Abstract: The present invention provides methods for identification of subjects with a rise in plasma coagulability post-diagnosis of thrombotic event (and consequent increased risk for recurrent thromboembolism) as well as for identification of subjects without thrombotic event who exhibit a rise in plasma coagulability for which prophylactic anticoagulation may be warranted for TE prevention, and other methods for identification of perioperative subjects who are at heightened risk for perioperative bleeding and/or for requiring blood transfusion, using the CloFAL assay, to aid in clinical decision making regarding anticoagulant and/or adjunctive clinical management designed to mitigate this heightened thromboembolic risk.

Abstract: The present invention provides methods for identification of subjects with a rise in plasma coagulability post-diagnosis of thrombotic event (and consequent increased risk for recurrent thromboembolism) as well as for identification of subjects without thrombotic event who exhibit a rise in plasma coagulability for which prophylactic anticoagulation may be warranted for TE prevention, and other methods for identification of perioperative subjects who are at heightened risk for perioperative bleeding and/or for requiring blood transfusion, using the CloFAL assay, to aid in clinical decision making regarding anticoagulant and/or adjunctive clinical management designed to mitigate this heightened thromboembolic risk.

Abstract: The present invention provides methods for identification of subjects with a rise in plasma coagulability post-diagnosis of thrombotic event (and consequent increased risk for recurrent thromboembolism) as well as for identification of subjects without thrombotic event who exhibit a rise in plasma coagulability for which prophylactic anticoagulation may be warranted for TE prevention, and other methods for identification of perioperative subjects who are at heightened risk for perioperative bleeding and/or for requiring blood transfusion, using the CloFAL assay, to aid in clinical decision making regarding anticoagulant and/or adjunctive clinical management designed to mitigate this heightened thromboembolic risk.

Abstract: Embodiments of the present invention report compositions and methods of analyzing thrombin and plasmin generation in a sample from a subject. In certain embodiments, the methods may comprise introducing at least one activator of coagulation and at least one activator of fibrinolysis to a sample and analyzing the sample for kinetic parameters related to thrombin and plasmin generation. In other embodiments, assays disclosed herein concern assessing net hemostatic balance of a subject for diagnostic and/or therapeutic applications.

Abstract: The present disclosure concerns methods of analyzing both clot formation and fibrinolysis in a sample, preferably simultaneously. In certain embodiments, the methods may comprise adding a small amount of at least one activator of coagulation and at least one activator of fibrinolysis to a sample and analyzing the sample for kinetic parameters related to clot formation and fibrinolysis. In another embodiment, the methods may comprise analyzing a sample from a subject for clot formation and fibrinolysis and detecting or diagnosing a disease or condition and/or applying information obtained from analyzing clot formation and fibrinolysis to determine a treatment for a medical condition of the subject.